NDAINTRAVENOUSPOWDER
Approved
Jul 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
VANCOMYCIN HYDROCHLORIDE (vancomycin hydrochloride) by Viatris is clinical pharmacology vancomycin is poorly absorbed after oral administration. First approved in 2018.
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Vancomycin hydrochloride is a glycopeptide antibiotic administered intravenously as a powder for reconstitution. It acts as a bactericidal agent by inhibiting bacterial cell-wall biosynthesis and altering cell-membrane permeability, with no cross-resistance to other antibiotic classes. It is a foundational therapy for serious gram-positive infections including methicillin-resistant Staphylococcus aureus (MRSA) and streptococcal infections.
Peak
Peak-stage mature product with stable market position; likely sustaining team focused on market defense and cost management rather than growth.
Mechanism of Action
CLINICAL PHARMACOLOGY Vancomycin is poorly absorbed after oral administration. In subjects with normal kidney function, multiple intravenous dosing of 1 g of vancomycin (15 mg/kg) infused over 60 minutes produces mean plasma concentrations of approximately 63 mcg/mL immediately after the completion…
Worked on VANCOMYCIN HYDROCHLORIDE at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.